ANG SAN MEI. SINGAPORE. EUROIMMUN (SEA) and Angsana Molecular & Diagnostics today build a strategic partnership on the allergy diagnostics and testing to support clinicians
, hospitals and private laboratories in South East Asia. This collaboration helps to bring the diagnostics and patient care synergies towards a better clinical management of patients with suspected allergies. Under the strategic collaboration, Angsana Molecular & Diagnostics would offer the comprehensive analysis of sensitizations against inhalation, food and other allergens to provide the precise determination of allergen. EUROIMMUN is committed with the customized two Allergy profiles to be well suited and cater to the region.
“There is a need for greater understanding on the risk of true poly-sensitizations for better patient management. With the simultaneous multi-parameter screening, the cooperation with EUROIMMUN gives us perfect position to take lead in allergy diagnostics and testing in the SEA region.” says Dr Chris Tan, Chief Executive Officer and founder of Angsana Molecular & Diagnostics. Dr Chris Tan added that “This partnership enables us to combine cost effective and accurate health screening providing an expanded, high-quality diagnostics service under the CAP-accredited environment”.
The significance of this cooperation and contribution from both partners are recognized by Li Chuan, President of APAC Group and Managing Director of EUROIMMUN (SEA) Pte Ltd. “Our collaboration with Angsana Diagnostics will provide a precise determination for Allergy diagnostics to benefit the patients with suspected allergies. Furthermore, EUROIMMUN
As a leading company in medical diagnostics, the cooperation between EUROIMMUN and Angsana Molecular & Diagnostics will play an important role in promoting the importance of diagnostics in the Asia Pacific region.
, Prof. Dr. Winfried Stöcker emphasized that “Asia Pacific region has been one of the important market for EUROIMMUN and we will continue to support the diagnostics market growth and development in Asia and EUROIMMUN, will and strive to enhance our collaboration with clinicians, medical providers to improve health outcomes and provide precise patient management.”